European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)

(2017) Wilson I. Gonsalves et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

(2017) Ute Hegenbart et al.   HAEMATOLOGICA

Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition

(2017) Miquel Granell et al.   HAEMATOLOGICA

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

(2017) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

(2017) C S Chim et al.   LEUKEMIA

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis

(2017) A D Wechalekar et al.   Blood Cancer Journal

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

(2017) Ute Hegenbart et al.   HAEMATOLOGICA

Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition

(2017) Miquel Granell et al.   HAEMATOLOGICA

Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia

(2016) Laetitia Souchet et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcomes of patients with renal monoclonal immunoglobulin deposition disease

(2016) Taxiarchis V. Kourelis et al.   AMERICAN JOURNAL OF HEMATOLOGY

Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia

(2016) Joshua N. Gustine et al.   AMERICAN JOURNAL OF HEMATOLOGY

Primary Plasma Cell Leukemia: Identity Card 2016

(2016) Pellegrino Musto et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Progress in the Treatment of Primary Plasma Cell Leukemia

(2016) Pellegrino Musto   JOURNAL OF CLINICAL ONCOLOGY

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

(2016) Morie A. Gertz et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome

(2016) Bruno Royer et al.   JOURNAL OF CLINICAL ONCOLOGY

Plasma cell leukemia: update on biology and therapy

(2016) Roberto Mina et al.   LEUKEMIA & LYMPHOMA

Primary plasma cell leukemia 2.0: advances in biology and clinical management

(2016) Antonino Neri et al.   Expert Review of Hematology

Lenalidomide is safe and active in Waldenström macroglobulinemia

(2015) Guillemette Fouquet et al.   AMERICAN JOURNAL OF HEMATOLOGY

Natural history and outcome of light chain deposition disease

(2015) Rabya H. Sayed et al.   BLOOD

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

(2015) V. Sanchorawala et al.   BLOOD

How I treat extramedullary myeloma

(2015) C. Touzeau et al.   BLOOD

A practical approach to the diagnosis of systemic amyloidoses

(2015) C. Fernandez de Larrea et al.   BLOOD

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study

(2015) E. Kastritis et al.   BLOOD

Rituximab intolerance in patients with Waldenström macroglobulinaemia

(2015) Jorge J. Castillo et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

(2015) E. Kastritis et al.   Clinical Lymphoma Myeloma & Leukemia

Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

(2015) Vittorio Simeon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

(2015) Anita D'Souza et al.   JOURNAL OF CLINICAL ONCOLOGY

Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens

(2015) Tilmann Bochtler et al.   JOURNAL OF CLINICAL ONCOLOGY

A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue

(2015) Janet A Gilbertson et al.   JOURNAL OF CLINICAL PATHOLOGY

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

(2015) Camille Cohen et al.   KIDNEY INTERNATIONAL

Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome

(2015) C. Karam et al.   NEUROLOGY

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

(2015) Duncan B. Richards et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial

(2015) K. Katayama et al.   BMJ Open

Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone

(2014) Tilmann Bochtler et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus

(2014) M. A. Dimopoulos et al.   BLOOD

Trends in survival of patients with primary plasma cell leukemia: a population-based analysis

(2014) W. I. Gonsalves et al.   BLOOD

Unexpected bone marrow finding in a patient with pancytopenia after hematopoietic stem cell transplantation

(2014) B. Drexler et al.   BLOOD

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia

(2014) S. P. Treon et al.   BLOOD

Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race

(2014) L. C. Edelstein et al.   BLOOD

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

(2014) D. E. Reece et al.   BLOOD

Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?

(2014) Maria Gkotzamanidou et al.   Clinical Lymphoma Myeloma & Leukemia

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

(2014) G Palladini et al.   LEUKEMIA

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

(2014) C P Venner et al.   LEUKEMIA

Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group

(2013) Eirini Katodritou et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

(2013) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation

(2013) Taiga Nishihori et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

(2013) M. A. Dimopoulos et al.   BLOOD

Outcomes of patients with POEMS syndrome treated initially with radiation

(2013) M. S. Humeniuk et al.   BLOOD

Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of Waldenström's Macroglobulinemia

(2013) Alessandra Tedeschi et al.   Clinical Lymphoma Myeloma & Leukemia

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach

(2013) G. Palladini et al.   HAEMATOLOGICA

Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis

(2013) Taxiarchis V. Kourelis et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

(2013) P Musto et al.   LEUKEMIA

Autologous stem cell transplant for light chain deposition disease: Incorporating bortezomib to the induction therapy

(2012) Victor H. Jimenez-Zepeda et al.   AMERICAN JOURNAL OF HEMATOLOGY

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

(2012) J. R. Mikhael et al.   BLOOD

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

(2012) C. P. Venner et al.   BLOOD

Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience

(2012) A. D'Souza et al.   BLOOD

Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant

(2012) N. Leung et al.   BLOOD

How I treat plasma cell leukemia

(2012) N. W. C. J. van de Donk et al.   BLOOD

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

(2012) E. Kastritis et al.   BLOOD

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

(2012) A. Dispenzieri et al.   BLOOD

Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   Clinical Lymphoma Myeloma & Leukemia

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

(2012) Shaji Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

(2012) S Z Usmani et al.   LEUKEMIA

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

(2012) H Landau et al.   LEUKEMIA

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

(2012) C Fernández de Larrea et al.   LEUKEMIA

The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients

(2011) A. Foli et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

(2011) Giovanni Palladini et al.   ANNALS OF HEMATOLOGY

Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party

(2011) G. D'Arena et al.   ANNALS OF ONCOLOGY

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients

(2011) S. O. Schonland et al.   BLOOD

Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome

(2011) J. Li et al.   BLOOD

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen

(2011) Steven P. Treon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Renal Monoclonal Immunoglobulin Deposition Disease: A Report of 64 Patients from a Single Institution

(2011) S. H. Nasr et al.   Clinical Journal of the American Society of Nephrology

Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience

(2011) Daniel Lebovic et al.   Clinical Lymphoma Myeloma & Leukemia

Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research

(2011) A Mahindra et al.   LEUKEMIA

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience

(2011) H Avet-Loiseau et al.   LEUKEMIA

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

(2010) P. Moreau et al.   BLOOD

Primary plasma cell leukemia and autologous stem cell transplantation

(2010) M. B. Drake et al.   HAEMATOLOGICA

Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis

(2010) Efstathios Kastritis et al.   JOURNAL OF CLINICAL ONCOLOGY

Kidney dysfunction during lenalidomide treatment for AL amyloidosis

(2010) R. Specter et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

(2009) G. Palladini et al.   CLINICAL CHEMISTRY

Proliferative Glomerulonephritis with Monoclonal IgG Deposits

(2009) S. H. Nasr et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia

(2008) S. P. Treon et al.   BLOOD

Treatment of light chain deposition disease with bortezomib and dexamethasone

(2008) E. Kastritis et al.   HAEMATOLOGICA

Genetic aberrations and survival in plasma cell leukemia

(2008) R E Tiedemann et al.   LEUKEMIA